August 11, 2020
3:00 PM GMT / 11:00 AM EDT
FHI Clinical is providing clinical operations services and expertise for the
We're pleased to announce six new members!
with the brave individuals across the U.S. who are demanding change for Black communities, and we stand with those working to advance equity and justice in all of the communities where we work worldwide.
Missed the webinar? Watch it now!
Missed the webinar? Watch it now!
that we've learned from previous outbreaks.
We envision a world where advances in vaccines and medicines help all people live longer, healthier lives.
We offer a unique combination of in-country technical, regulatory and cultural knowledge and an established global presence in Africa, Asia, Europe, Latin America and North America.
We adapt our processes and workflow as your study needs change. No matter how large or small the project, we remain agile and exact, because your research demands it.
We have research at our core. A subsidiary of FHI 360, we benefit from our parent company’s 40+ year history of clinical research and success in creating and growing CROs.
Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.
Let us help you enter hard-to-reach markets and access the right patient populations.
Tailored services to meet your needs, from protocol design and site assessments to trial planning, implementation and management.
Ability to address challenges across dozens of therapeutic areas, including infectious diseases (IDs), neglected tropical diseases (NTDs), emerging and reemerging diseases, and pediatric studies.
Leverage established partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Agency for International Development (USAID).
As we monitor the rapidly changing COVID-19 situation, reliable data sources are crucial. We recommend this resource from Johns Hopkins University to better understand the pandemic’s impact.
The data sources include the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Center for Disease Prevention and Control, the National Health Commission of the People’s Republic of China, 1point3acres, Worldometers.info, BNO, state and national government health departments, local media reports, and the DXY, one of the world’s largest online communities for physicians, health care professionals, pharmacies and facilities.
August 4, 2020
FHI Clinical is pleased to announce our partnership with Tiziana Life Sciences to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
August 11, 2020
Patient safety and data integrity remain of utmost importance as CROs navigate shifting regulatory guidelines, reevaluate their existing strategies and reprioritize IT projects. Register to learn how the pandemic has transformed the clinical trial landscape, the operational shifts that are needed within CROs, the technologies that have been most impactful and some of the obstacles and barriers to transformation.
The industry’s response to outbreaks like COVID-19 will continue to push advances in technology and influence the way we conduct clinical research. Challenges we’ve faced trying to adhere to impossible timelines and budgets have solidified the need for a technology platform that includes three main characteristics: unified, modular and cloud-based.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA